Event Calendar

Nov 4 - Nov 17, 2020

PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present at two investor conferences in November. Details on the presentations can be found below. The company will also participate in one-on-one investor meetings at the AGP Virtual Healthcare Symposium 2020 on Thursday, November 19.


H.C. Wainwright 6th Annual Israel Conference

Date:  Thursday, November 12, 2020
Time: 1:30 PM Eastern Time


Stifel 2020 Virtual Healthcare Conference

Date:  Tuesday, November 17, 2020
Time: 8:00 AM Eastern Time
Webcast: https://wsw.com/webcast/stifel27/pypd/2115344 

Jun 6 - Jun 10, 2020
PolyPid’s abstract "Local Constant Prolonged Release of an Antibiotic for the Prevention of Surgical Site Infections (SSI) Post Colorectal Resection Abdominal Surgeries" was accepted for quick Shot Presentation during ASCRS’ Annual Scientific Meeting. Due to the COVID-19 pandemic the personal meeting was cancelled, however, PolyPid's slides and voice narration, presented by Dr. Anthony Senagore, will remain posted on the ASCRS virtual meeting website from June 6th until the 2021 ASCRS Annual Scientific Meeting in April.

Sep 25 - Sep 28, 2020
PolyPid’s abstract "Improved healing of severe open long bone fractures treated with antibiotic-formulated bone graft during the first surgical intervention post-injury" was accepted for Oral presentation at the 2019 OTA Annual Meeting, to be held in Colorado, Denver, on September 25-28, 2019. The Oral Free Paper will be presented by Prof. Doron Norman, in Paper Session II: Tibia and Knee/Tibial Plateau, on Fri., 9/27/19 at 10:16 AM - 10:22 AM.  

Nov 25 - Nov 28, 2018
PolyPid will present its product candidate D-PLEX intended to treat peri-implantitis,  in booth no. 413 at the Israeli pavilion, in the Greater New York Dental Meeting, to be held on November 25th - 28th 2018, in the Jacob K. Javits Convention Center, 11th Ave B/W 34th & 39th Street, David Intercontinental hotel, New York.

Oct 10 - Oct 13, 2018
PolyPid’s abstract “Enhanced bone healing of Gustilo III severe open tibia fractures treated by immediate antibiotic-formulated bone grafting” was accepted for Oral presentation at the 39th SICOT Orthopaedic World Congress, to be held in Montreal, Canada, from 10-13 October 2018. The Oral Free Paper will be presented by Dr. Noam Emanuel, PolyPid’s CTO, as a part of the Trauma Free Papers (Pelvis/Lower Limb) session, currently due to take place on 10/12/2018 at 16:00 - 17:30 in Room 517d.

Oct 7 - Oct 9, 2018
PolyPid’s abstract “PLEX technology - A lipid-and-polymer-based novel local drug delivery system - from concept to clinical practice” was accepted for Oral presentation at the 11th meeting of the ICRS, to be held on October 7-9, 2018, at the Hacienda Forest View Hotel, Ma'alot Tarshiha. The presentation is scheduled for Sunday, October 7, 2018 from 15:20 until 15:35  in the session entitled:  INNOVATIVE BIO-INSPIRED AND BIOMIMETIC MATERIALS.

May 15 - May 17, 2018
PolyPid will participate at IATI BioMed (Biomed Israel 2018), Israel’s 17th National Life Sciences & technology Week, to be held May 15 - 17, 2018, at the Tel Aviv Convention Center, Israel. The company will be also presenting at the Start Up Pavilion by Israel Innovation Authority, on May 16 (Booth SP16).

Mar 12 - Mar 14, 2018
PolyPid will participate at the DDF Summit Meeting, to be held in Berlin, Germany.  PolyPid will be represented by Dr. Tamar Alon, PolyPid’s Chief Business Officer. PolyPid will be exploring new collaborations around its revolutionary PLEX™ localized, controlled and prolonged drug delivery platform and products.


PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >


Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >


Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >